Shift from cytoplasmic to nuclear maspin expression correlates with shorter overall survival in node-negative colorectal cancer

Human Pathology

Volumn 41, Issue 7, 2010, Pages 1024-1033

  Märkl, Bruno ^a   Arnholdt, Hans M ^a   Jähnig, Hendrik ^a   Schenkirsch, Gerhard ^b   Herrmann, Robert A ^a   Haude, Karlheinz ^a   Spatz, Hanno ^a   Anthuber, Matthias ^a   Schlimok, Günther ^a   Oruzio, Daniel ^a  

^a KLINIKUM AUGSBURG   (Germany)

^b Clinical and population based cancer registry Augsburg   (Germany)

Author keywords

Colorectal cancer; Immunohistochemistry; Maspin

Indexed keywords

MASPIN;

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; CYTOPLASM; DISEASE COURSE; FATALITY; FEMALE; HIGH RISK POPULATION; HUMAN; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROSPECTIVE STUDY; SURVIVAL TIME;

AGED; CELL NUCLEUS; COLORECTAL NEOPLASMS; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SERPINS;

EID: 77953285071     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.10.021     Document Type: Article

References (37)

1. Zou Z., Anisowicz A., Hendrix M.J., et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263 (1994) 526-529
2. Umekita Y., and Yoshida H. Expression of maspin is up-regulated during the progression of mammary ductal carcinoma. Histopathology 42 (2003) 541-545
3. Lee M.J., Suh C.H., and Li Z.H. Clinicopathological significance of maspin expression in breast cancer. J Korean Med Sci 21 (2006) 309-314
4. Zou Z., Zhang W., Young D., et al. Maspin expression profile in human prostate cancer (CaP) and in vitro induction of maspin expression by androgen ablation. Clin Cancer Res 8 (2002) 1172-1177
5. Secord A.A., Lee P.S., Darcy K.M., et al. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. Gynecol Oncol 101 (2006) 390-397
6. Zheng H.C., Saito H., Masuda S., et al. Cytoplasmic and nuclear maspin expression in lung carcinomas: an immunohistochemical study using tissue microarrays. Appl Immunohistochem Mol Morphol 16 (2008) 459-465
7. Boltze C., Schneider-Stock R., Meyer F., et al. Maspin in thyroid cancer: its relationship with p53 and clinical outcome. Oncol Rep 10 (2003) 1783-1787
8. Woenckhaus M., Bubendorf L., Dalquen P., et al. Nuclear and cytoplasmic maspin expression in primary non-small cell lung cancer. J Clin Pathol 60 (2007) 483-486
9. Cao D., Zhang Q., Wu L.S., et al. Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases. Mod Pathol 20 (2007) 570-578
10. Song S.Y., Son H.J., Kim M.H., et al. Prognostic significance of maspin expression in human gastric adenocarcinoma. Hepatogastroenterology 54 (2007) 973-976
11. Yu M., Zheng H., Tsuneyama K., et al. Paradoxical expression of maspin in gastric carcinomas: correlation with carcinogenesis and progression. Hum Pathol 38 (2007) 1248-1255
12. Song S.Y., Lee S.K., Kim D.H., et al. Expression of maspin in colon cancers: its relationship with p53 expression and microvessel density. Dig Dis Sci 47 (2002) 1831-1835
13. Boltze C. Loss of maspin is a helpful prognosticator in colorectal cancer: a tissue microarray analysis. Pathol Res Pract 200 (2005) 783-790
14. Sheng S. A role of novel serpin maspin in tumor progression: the divergence revealed through efforts to converge. J Cell Physiol 209 (2006) 631-635
15. Khalkhali-Ellis Z., Christian A.L., Kirschmann D.A., et al. Regulating the tumor suppressor gene maspin in breast cancer cells: a potential mechanism for the anticancer properties of tamoxifen. Clin Cancer Res 10 (2004) 449-454
16. Sheng S. The promise and challenge toward the clinical application of maspin in cancer. Front Biosci 9 (2004) 2733-2745
17. Zheng H., Tsuneyama K., Cheng C., et al. Maspin expression was involved in colorectal adenoma-adenocarcinoma sequence and liver metastasis of tumors. Anticancer Res 27 (2007) 259-265
18. Bettstetter M., Woenckhaus M., Wild P.J., et al. Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer. J Pathol 205 (2005) 606-614
19. Dietmaier W., Bettstetter M., Wild P.J., et al. Nuclear maspin expression is associated with response to adjuvant 5-fluorouracil based chemotherapy in patients with stage III colon cancer. Int J Cancer 118 (2006) 2247-2254
20. Warusavitarne J., and Schnitzler M. The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis 22 (2007) 739-748
21. Investigators I.B. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) investigators. J Clin Oncol 17 (1999) 1356-1363
22. Gill S., Loprinzi C.L., Sargent D.J., et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol 22 (2004) 1797-1806
23. O'Connell J.B., Maggard M.A., and Ko C.Y. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96 (2004) 1420-1425
24. Harrison J.C., Dean P.J., el-Zeky F., et al. Impact of the Crohn's-like lymphoid reaction on staging of right-sided colon cancer: results of multivariate analysis. Hum Pathol 26 (1995) 31-38
25. Jass J.R., Ajioka Y., Allen J.P., et al. Assessment of invasive growth pattern and lymphocytic infiltration in colorectal cancer. Histopathology 28 (1996) 543-548
26. Ueno H., Murphy J., Jass J.R., et al. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 40 (2002) 127-132
27. Johnston P.G. Stage II colorectal cancer: to treat or not to treat. Oncologist 10 (2005) 332-334
28. Marioni G., Blandamura S., Giacomelli L., et al. Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease-free interval after surgery for squamous cell carcinoma of the larynx. Histopathology 46 (2005) 576-582
29. Umekita Y., Ohi Y., Sagara Y., et al. Expression of maspin predicts poor prognosis in breast-cancer patients. Int J Cancer 100 (2002) 452-455
30. Mohsin S.K., Zhang M., Clark G.M., et al. Maspin expression in invasive breast cancer: association with other prognostic factors. J Pathol 199 (2003) 432-435
31. Lonardo F., Li X., Siddiq F., et al. Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer 51 (2006) 31-39
32. Solomon L.A., Munkarah A.R., Schimp V.L., et al. Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. Gynecol Oncol 101 (2006) 385-389
33. Surowiak P., Materna V., Drag-Zalesinska M., et al. Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cells and for ovarian cancer cases of longer survival rates. Int J Gynecol Pathol 25 (2006) 131-139
34. Popat S., Hubner R., and Houlston R.S. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23 (2005) 609-618
35. Prall F., Nizze H., and Barten M. Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology 47 (2005) 17-24
36. Nakamura T., Mitomi H., Kanazawa H., et al. Tumor budding as an index to identify high-risk patients with stage II colon cancer. Dis Colon Rectum 51 (2008) 568-572
37. Prall F. Tumour budding in colorectal carcinoma. Histopathology 50 (2007) 151-162